GL Pharmtech

What GL Pharmtech does

GL Pharmtech (지엘팜텍 주식회사) is a South Korean, KOSDAQ-listed pharmaceutical company specializing in improved new drug development (개량신약), generic drug formulations, and novel drug development built on proprietary drug delivery technology platforms. Headquartered in Seongnam, Gyeonggi Province, with a workforce of 11-50 employees, the company focuses on four formulation technology platforms: controlled-release (exemplified by Kabalin CR / pregabalin extended-release), orally disintegrating tablet (ODT) technology (exemplified by the Rosuvastatin/Ezetimibe oral dissolving tablet), enteric coating (exemplified by Parence), and topical formulations (exemplified by Acenon Cream and GL Ibutok Cream 5%). The company holds granted patents on its pregabalin extended-release technology in China (1 patent, 2021) and Japan (2 patents, 2020), establishing a documented IP footprint outside Korea.

The commercial portfolio comprises six marketed products: four prescription drugs — Kabalin CR Extended-Release Tablet (CNS), Parence Enteric Coated Tablet (intestinal delivery), GL Ibutok Cream 5% (topical), and G Soren Tablet (digestive ulcers) — and two OTC products, Zenstrin Troche and Champles Syrup. Distribution runs through South Korean licensed pharmaceutical wholesalers serving hospitals, clinics, and pharmacies; the company does not employ direct-to-consumer marketing. Pricing is not publicly disclosed and is subject to South Korean national health insurance reimbursement regulation.

The company emerged from a 2016 reverse merger with an IBCS SPAC and a 2019-2020 financial distress episode that triggered a KOSDAQ Investment Caution Stock designation (2020-05-04), which was removed in 2021-04-30. Corporate governance has been restructured, with co-representative directors Jin Seong-pil and Kim Yong-il (진성필 / 김용일) succeeding former director Wang Hoon-sik. The company has pursued — and withdrawn, then reannounced — a small-scale merger with related party GL Pharma (지엘파마) in 2025 and 2026, signaling a sustained consolidation strategy. Most recent operational signals include reported Q1 revenue growth of approximately 20% YoY with profitability achieved and an imminent new drug approval for the Rosuvastatin/Ezetimibe ODT and Kabalin CR pipeline products.

Name

GL Pharmtech

Legal name

지엘팜텍 주식회사

Website

https://glpt.co.kr

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

GL Pharmtech is a South Korean KOSDAQ-listed pharmaceutical company that develops and markets improved new drugs and generics using proprietary controlled-release, ODT, enteric coating, and topical formulation technologies, serving South Korean healthcare providers through wholesale distribution.

Ownership category

akta.pro rank

Product category

Pharmaceutical Formulations

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical formulations
• Controlled-release tablets
• Improved new drugs
• Drug delivery technology
• Generic drug development

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels1 record

Core offering

GL Pharmtech develops, manufactures, and commercializes prescription and OTC pharmaceutical products in South Korea, with a strategic focus on improved new drugs (개량신약) developed through proprietary drug delivery technologies including controlled-release, enteric coating, oral dissolving tablet, and topical formulation platforms. The company's marketed portfolio spans CNS, cardiovascular, gastrointestinal, and dermatological therapeutic areas, distributed via licensed pharmaceutical wholesalers to hospitals, clinics, and pharmacies. Pipeline work includes novel drugs, improved formulations (자료제출의약품), and generic drugs.

Product overview

GL Pharmtech is a pharmaceutical company specializing in drug formulation development with a focus on improved new drug development (개선신약). The company operates as a drug development-focused pharmaceutical enterprise targeting improved formulations using advanced drug delivery technology. The product portfolio includes six marketed products: four prescription drugs (KabalIN CR Extended-Release Tablet for CNS applications, Parence Enteric Coated Tablet for intestinal delivery, GL Ibutok Cream 5% for topical use, and G Soren Tablet for digestive ulcers) and two over-the-counter products (Zenstrin Troche for oral cavity and Champles Syrup). The company is pursuing new drug development pipelines including novel drugs, improved formulations, and generic medications, with research achievements in controlled-release tablets, enteric-coated formulations, and topical cream preparations.

Differentiator

Problem solved

Functional benefit

Products and services

• KabalIN CR Extended-Release Tablet (카발린CR서방정) A prescription central nervous system (CNS) medication (pregabalin class) formulated as an extended-release tablet using the company's proprietary controlled-release drug delivery technology, designed to reduce dosing frequency and improve patient compliance in the treatment of neuropathic pain and seizure disorders. Distributed to South Korean hospitals, clinics, and pharmacies via licensed pharmaceutical wholesalers.
• Parence Enteric Coated Tablet (파렌스장용정) A prescription gastrointestinal medication formulated as an enteric-coated tablet designed for targeted release in the intestinal tract, providing gastric protection of acid-labile active ingredients and reducing gastric side effects for patients with acid-related GI conditions. Distributed to South Korean hospitals, clinics, and pharmacies via licensed pharmaceutical wholesalers.
• GL Ibutok Cream 5% (지엘이부톡크림5%) A prescription topical cream formulation containing 5% ibutox (ibuprofen topical) developed using the company's proprietary topical formulation technology, intended for dermatological applications. Distributed to South Korean hospitals, clinics, and pharmacies via licensed pharmaceutical wholesalers.
• Champles Syrup (잼플시럽) An over-the-counter syrup formulation for general patient use. Sold through licensed pharmacies in South Korea.
• Zenstrin Troche (젠스트린트로키) An over-the-counter troche (lozenge) formulation intended for dental and oral cavity applications. Sold through licensed pharmacies in South Korea.
• G Soren Tablet (지소렌정) A prescription oral tablet for the treatment of digestive ulcers, positioned in the gastrointestinal therapeutic area. Distributed to South Korean hospitals, clinics, and pharmacies via licensed pharmaceutical wholesalers.
• Acenon Cream (애크논크림) A dermatological topical cream product developed using the company's proprietary topical formulation technology, listed among the company's key R&D achievements and marketed products.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• GLPharma (지엘파마 주식회사)coreStrategic or Co-development Partner · 6 August 2025GL Pharmtech planned to absorb-merge with GLPharma (지엘파마 주식회사) via a small-scale merger (소규모 합병) under Korean Commercial Code Article 527-3. The merger was announced on August 6, 2025 with a planned effective date of September 11, 2025. The merger ratio was specified as GL Pharmtech : GLPharma = 1:0. However, the merger was subsequently withdrawn on August 14, 2025 due to institutional/regulatory concerns that would have caused economic losses. A new merger announcement was made on June 12, 2026.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Hanmi Pharmaceutical: Korean specialty pharmaceutical company developing improved formulations, controlled-release drugs, and novel drug delivery platforms — directly comparable to GL Pharmtech's formulation-focused R&D model, though at much larger scale.
• Dong-A Pharmaceutical: Korean pharma with diverse branded generics and improved formulation portfolio, including topical and oral products, competing in similar therapeutic areas as GL Pharmtech.
• Daewoong Pharmaceutical: Major Korean pharmaceutical company with strong formulation development and generic/improved drug portfolio, serving similar CNS, GI, and dermatology therapeutic categories with overlapping patient channels.
• Bukwang Pharmaceutical: Mid-sized Korean pharmaceutical company focused on specialty generics and improved formulations across CNS, GI, and dermatology categories, with a comparable small/mid-cap KOSDAQ profile.
• Kukje Pharma: Korean pharmaceutical company focused on improved new drugs and formulation development, similar therapeutic focus and small/mid-cap KOSDAQ-listed profile to GL Pharmtech.
• Chong Kun Dang Pharmaceutical: Korean pharmaceutical company focused on generic drugs and improved formulations across cardiovascular, CNS, and GI categories — directly comparable product mix and domestic market positioning.
• JW Pharmaceutical: Korean pharmaceutical company developing generic and improved formulations with focus on CNS, cardiovascular, and dermatology — similar scale, formulation technology emphasis, and domestic channel strategy.
• Daehan New Pharm: Korean pharmaceutical manufacturer of generic and improved formulations, with overlapping CNS, cardiovascular, and dermatology product lines and similar mid-cap KOSDAQ positioning.
• Ahn-Gook Pharmaceutical: Korean generics manufacturer with portfolio spanning cardiovascular, CNS, and GI categories — comparable formulation focus, domestic distribution model, and small/mid-cap KOSDAQ scale.

Broad incumbents

• Yuhan Corporation: Large established Korean pharmaceutical company with broad branded and generic drug portfolio across CNS, cardiovascular, and GI — much larger scale but comparable therapeutic categories and distribution model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GL Pharmtech